Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28803989 | 0.88 | RAB9A (0.58) | ESR2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL28792823 | 0.86 | MEN1 (0.50) | ESR2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9109376 | 0.86 | MAOB (0.52) | ESR2RAB9ANPC1SMN1; SMN2ADORA3 | |
| SCHEMBL9114545 | 0.85 | ESR2 (0.57) | ESR2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL17731528 | 0.84 | CYP11B2 (0.49) | ESR2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL29472984 | 0.81 | ADORA1 (0.59) | ESR2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL28541224 | 0.81 | ADORA1 (0.59) | ESR2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL1872760 | 0.81 | HTT (0.57) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL11685099 | 0.79 | ESR2 (0.54) | ESR2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL28539726 | 0.79 | NPC1 (0.52) | ESR2RAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184598-A | Photocatalytic preparation method and application of N- (2-phenyl-2H-indazole-3-yl) benzamide compound | 河南师范大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-113698349-B | Aqueous phase photocatalysis preparation method of 2- (2-phenyl-2H-indazole-3-yl) acetate compound | 河南师范大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-116332851-A | Cyanomethyl phenyl indazole compound and preparation method thereof | 河南中医药大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-115613060-A | Method for synthesizing C-3 phosphorylated 2H-indazole compound by direct electrochemical oxidation | 浙江工业大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-114989089-A | Photocatalytic preparation method of 3-alkyl-2-phenyl indazole compound | 河南师范大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-114805209-A | Preparation method of visible light induced 3-aryl-2H-indazole compound | 河南工程学院 | 2022-07-29 | — | — | CN | disclosed |
| CN-113698349-A | Water-phase photocatalytic preparation method of 2- (2-phenyl-2H-indazole-3-yl) acetate compounds | 河南师范大学 | 2021-11-26 | — | — | CN | disclosed |
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | ESR2 270/4885RAB9A 3355/4885MEN1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.